Biotech Co (Country/ Symbol) Pharma Co (Country/ Symbol) Type/ Product Area Amount (M) Terms/ Details (Month) Access Pharmaceuticals Inc. (OTC BB:AXCS) Mipharm SpA (Italy) Various formulations of amlexenox for treating several diseases, including mucositis, oral lichenplanus and atopic dermatitis ND Mipharm gains marketing rights for Italy, Switzerland, Turkey and Lebanon; Access has granted Mipharm manufacturing rights for Europe for the products; Mipharm will make an equity investment in

company submitted amendment to NDA that includes data from Phase III PURSUIT trial (10/20) Gilead Sciences Inc

Actimmune Interferon gamma-1b Osteopetrosis Actimmune, already approved for chronic granulomatous disease, received approval to treat osteopetrosis (2/00) Genetics Institute of Wyeth-Ayerst Laboratories (subsidiary of American Home Products Corp. ReFacto Recombinant antihemophiliac factor VIII Hemophilia A and short-term prophylaxis to reduce bleeding FDA approved ReFacto for control and prevention of bleeding and surgical prophylaxis with hemophilia A patients (3/00) Gilead Sciences

Gilead Sciences GILD 25 22.875 27.625 44.375 38.25 53 Gliatech GLIA 7.75 10.125 8.25 11.75 10.25 32 Guilford Pharm GLFD 23.25 20.75 24.25 29.5 20.125 -13 Hemacare HEMA 3.125 2.375 1.687 1 0.468 -85 Human Genome HGSI 40.75 32.5 33.25 43.062 39.75 -2 Hycor Bio HYBD 3 2.625 2.031 2.281 1.562 -48 Hyseq HYSQ 14 ------- ------- 19.875 9.625 -31 IBAH IBAH 6.75 6.375 3.562 4.75 3.75 -44 ICN Pharma

Biotech Co (Country/ Symbol) Pharma Co (Country/ Symbol) Type/ Product Area Amount (M) Terms/Details (Month) 3-Dimensional Pharmaceuticals Inc. (DDDP) DuPont Pharmaceuticals Co. (unit of E.I. DuPont de Nemours & Co.; NYSE:DD) Research collaboration/target discovery and use of 3DP s DirectedDiversity technology to generate combinatorial chemistry libraries for drug discovery $9 3DP will generate custom libraries and optimize them to obtain preclinical candidates; for the initial target

Gilead Sciences GILD 25 38.25 53 Bioreliance BREL 15 23 53 Molec Dynam MDYN 10.75 16.25 51 T Cell Sci TCEL 1.625 2.437 50 Lifecell LIFC 3.125 4.625 48 ArQule ARQL 15.75 22.937 46 OncorMed ONM 4.812 7 45 Novavax NOX 3.437 5 45 IDEC Pharm IDPH 23.75 34.375 45 CV Therapeutics CVTX 6.5 9.375 44 Alexion Pharma ALXN 8.687 12.5 44 Parexel Intl PRXL 25.813 37 43 Texas Biotech TXB 4.375 6.187 41 MacroChem MCHM 6.5 9.125 40 Draxis

Company (Country/ Symbol) Company (Country/ Symbol) Type/ Product Area Terms/Details (Month) Abgenix Inc. (ABGX) Gliatech Inc. (GLIA) License and option agreement/use of Abgenix s XenoMouse technology to generate fully human monoclonal antibodies to the complement protein properdin for use in the fields of cardiovascular and inflammatory diseases Abgenix will receive a technology an access payment and could receive additional fees and milestones, plus royalties on product sales; Gliatech will

Company Product Marketer Indication (U.S. Approval Date) Abbott Laboratories Inc. HIVAG-1 monoclonal antibody Abbott Laboratories Inc. Diagnostic for use in blood banks and plasma centers, and for prognostic use in HIV patients (4/96) Abbott Laboratories Inc. Norvir Abbott Laboratories Inc. Treatment of advanced AIDS (for use alone or in combination with nucleoside analogues); also treatment of earlier-stage AIDS (3/96) Activated Cell Therapy Inc. (now Dendreon Corp.) Devices used for

The latter figure assumes conversion by Elan of $20 million in convertible notes still outstanding. • OSI Pharmaceuticals Inc., of Melville, N.Y., and Gilead Sciences Inc., of Foster City, Calif., said they completed the sale of Gilead’s oncology assets to OSI

Antisense gains the right to commercialize ISIS 107248 (ATL 1102), a candidate for multiple sclerosis (11/21**) Archemix Inc.* Gilead Sciences Inc. (GILD) Licensing agreement for Gilead's aptamer technology Archemix will pay $17.5M for the license (10/25) Argenta Discovery Ltd. (UK)* De Novo Pharmaceu- ticals Ltd. (UK)* Collaboration directed toward certain De Novo drug discovery targets Argenta will provide De Novo with synthetic chemistry and screening services for

Gilead Sciences Inc. (GILD) GS 7836 Anticancer nucleoside analogue Cancer Company initiated a Phase I trial in Canada (11/14) Gilead Sciences Inc. (GILD) GS 7904L Liposomal thymidylate synthase inhibitor Cancer Company began a Phase I trial in Germany (11/28) Immuno- Designed Molecules SA (France)* MAK IDM-activated macrophage cells Bladder cancer Phase I/II trial data showed the therapy significantly reduced tumor recurrence

Company* (Symbol) Product Description Indication Status (Date) CANCER Allos Therapeu- tics Inc. (ALTH) RSR13 Synthetic allosteric modifier of hemoglobin that noncovalently binds to hemoglobin, increasing oxygen delivery to hypoxic tissue Non-small-cell lung cancer Company updated survival results from a Phase II trial showing a median survival rate of 20.6 months (11/6) AnorMED Inc. (Canada; TSE: AOM) AMD-3100 Inhibits the binding action of HIV with the CXCR4

The optimization in dosing regimen has the potential to yield an improved safety and efficacy profile for the combination of squalamine and the chemotherapy agents. • Gilead Sciences Inc., of Foster City, Calif., began the first Phase I trial of GS7904L, an investigational liposomal thymidylate synthase inhibitor for the potential treatment of cancer, in Germany

By Randall Osborne West Coast Editor In a whopper deal that follows holiday feasting, Gilead Sciences Inc. – with approval of the HIV drug Viread under its belt – is shoveling onto OSI Pharmaceuticals Inc.’s plate the entire Gilead oncology business, for up to $200 million in cash and stock

Gilead Sciences Inc., of Foster City, Calif., appointed Gayle Wilson to its board

Specific trials were requested in a broad group of diseases, including cancer of the prostate, breast, lung, colon, bladder, ovary, uterus, kidney and pancreas, as well as in Merkel cell tumor and non-Hodgkin’s lymphoma. • Gilead Sciences Inc., of Foster City, Calif., initiated the first Phase I clinical trial of GS7836, an anticancer nucleoside analogue, in Canada

None of the control mice treated with bovine serum albumin survived. • Gilead Sciences Inc., of Foster City, Calif., reported data from Study 435 of adefovir dipivoxil 10 mg once daily in post-liver transplant patients with lamivudine-resistant chronic hepatitis B virus infection

Gilead Sciences Inc., of Foster City, Calif., reported results from a large, multinational Phase III trial that demonstrated adefovir dipivoxil 10 mg significantly improved liver function and reduced levels of virus in patients with chronic hepatitis B virus (HBV) infection

Gilead Sciences Inc. (GILD) Viread Tenofovir disoproxil fumarate HIV FDA Antiviral Drugs Advisory Committee was split on the drug with nine members supporting a restricted label and seven members supporting a broad use (10/3